Aspire Biopharma (ASBP) Jumps on $100M Equity Line and Q3 Filing – What Matters on November 14, 2025
Micro‑cap biotech Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) is back in the spotlight today after securing a new $100 million equity line of credit and releasing its Q3 2025 10‑Q, sending the stock sharply higher in pre‑market trading. ASBP stock among Friday’s biggest pre‑market movers Aspire Biopharma shares were one of the most active health‑care names in U.S. pre‑market trade on Friday. StockTitan data places Aspire’s current market capitalization at roughly $5.3 million, with a public float of about 27.2 million shares and insider ownership above 30%. Stock Titan Today’s move comes as investors digest two major disclosures: a fresh